Skip to main content
. 2021 Nov 3;11(1):187–199. doi: 10.1007/s40121-021-00556-x

Fig. 2.

Fig. 2

Adjusted odds of AKI for colistin versus βL + βLI agents, stratified by baseline renal disease, among propensity score-matched sample